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Anesthesiology, University of Messina, ItalyAbstractAirway inﬂammation plays a central role in cystic ﬁbrosis (CF) lung disease, and biomarkers of inﬂammation, such as high-mobility group box
1 (HMGB1) could be used to monitor disease activity. The main aim of this study was to conﬁrm the role of HMGB1 in CF patients,
correlating its serum and sputum levels with pulmonary function and inﬂammation. Serum and sputum HMGB1 were evaluated in a
cohort of 31 CF patients and 30 non-smoking healthy subjects (HS group). Acute pulmonary exacerbation events and lung function
decline have been also evaluated during a 3-year follow-up period. Serum HMGB1 levels were signiﬁcantly higher than those measured in
HS, such as sputum HMGB1. Kaplan-Meier survival curves revealed that patients with high HMGB1 values experienced a signiﬁcantly
faster evolution to decline of lung function. A multiple Cox regression analysis assessed that an increase of serum HMGB1 was associated
with 5% increased risk of pulmonary disease progression, whereas elevated sputum HMGB1 was related to a 10% increased risk of lung
function decline. In CF patients, HMGB1 closely reﬂects the entity of pulmonary impairment and represents a strong and independent
risk marker for progression of lung function decline.
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These authors contributed equally to this workIntroductionSurvival in cystic ﬁbrosis (CF) has increased signiﬁcantly in the
past 30 years due to therapeutic advances, with a consequent
delay in the progressive decline in lung function [1].
However, Pseudomonas aeruginosa infection is still one of the
most prevalent bacterial pathogens affecting the majority of CFMicrobiol Infect 2015; 21: 368.e1–368.e9
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.004patients and negatively inﬂuencing their outcomes, despite
intensive antibiotic regimens and innovative therapies [2].
Several preventive strategies have been adopted in recent years
to detect the infection early, such as serology tests adjunct to
respiratory culture methods, but this infection is still closely
tied to the progression of CF lung disease, frequency of hos-
pitalization, and decreased survival [3,4].
The mechanisms of chronic airway inﬂammation are not fully
elucidated, although many components of the innate immune
response in CF lung disease have been typiﬁed [5] (Fig. 1).
Monitoring the expression of biomarkers that are predictive
of pulmonary exacerbation and/or infection would potentially
help to prolong the survival of CF subjects, by helping to dictate
short- and long-term therapy, minimizing cumulative lungious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Chirico et al. HMGB1 and lung function decline in cystic ﬁbrosis 368.e2damage as a consequence of these cycles of infection and
inﬂammation.
Forced expiratory volume in the ﬁrst second (FEV1) is uni-
versally adopted as a surrogate outcome, but it seems to be
poorly sensitive in evaluating lung disease progression in CF [6].
Bronchoalveolar lavage (BAL) remains the primary method of
interrogating the inﬂammatory status of the airway, but the
procedure is invasive and the inﬂammatory proﬁles in the lung
segments sampled may not accurately represent the lung as a
whole. On the other hand, induced sputum analysis offers safety
advantages over BAL ﬂuid samples, providing effective mea-
surements, although questions still exist regarding the repro-
ducibility of this approach [7].FIG. 1. Pathogenesis of inﬂammation, infection, and HMGB1 role in the CF
process, with the activation of neutrophils (PMNs) and macrophages and subs
in turn, leads to the release of prominent levels of interleukin-8, the major neu
tissue and alveolar macrophages are activated with airway bacterial colonizatio
including HMGB1. PMNs actively release a variety of inﬂammatory products an
upregulates pro-inﬂammatory cytokine expression via its cellular receptors,
receptor (TLR)-2 and -4. CFTR, cystic ﬁbrosis trans-membrane conductanc
macrophage; PA, Pseudomonas aeruginosa; PMN, polymorphonuclear leukocyt
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InIn recent decades, the widespread use of high-performance
analytical technology and the development of miniaturized
control and processing systems have opened enormous pros-
pects for breath diagnosis as a non-invasive diagnostic tool for a
variety of diseases, including CF [8,9]. In particular, proteomics
provides the ability to characterize proteins in complex solu-
tions, such as sputum, offering a greater understanding of the
physiopathology of the lung environment in CF [10].
High-mobility group box 1 (HMGB1) could play a prominent
role in the enhanced inﬂammatory responses in CF lungs, acting
on tissue repair, neutrophilic recruitment, direct inhibition of
macrophage ability to phagocytose bacteria, and activating
multiple inﬂammatory signals through the interaction with itsairway. Inﬂammation and bacterial colonization initiate the pathological
equent activation of NF-kappa B-mediated inﬂammatory response. This,
trophil chemoattractant in the lung, and HMGB1 in the CF airways. Both
n, leading to the active release of a host of pro-inﬂammatory mediators,
d, passively as a result of PMN apoptosis or necrosis, HMGB1. HMGB1
the receptor for advanced glycation end products (RAGE) and toll-like
e regulator; HMGB1, high-mobility group box 1; IL, interleukin; MCP,
es; SA, Staphylococcus aureus.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e1–368.e9
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for advanced glycation end-product [11,12]. Previous reports of
HMGB1 activity have focused on its importance as a mediator
of acute inﬂammation of the lung, demonstrating its elevated
levels in CF airways, closely relating with neutrophil inﬂux and
lung matrix degradation [13–15]. Moreover, it was also
revealed in sputum samples, although it was not clear whether
elevated levels of HMGB1 were mainly released from apoptotic
leukocytes [16].
The main aim of this study was to conﬁrm the role of
HMGB1 in CF patients, correlating its serum and sputum levels
with acute pulmonary exacerbation (APE) and lung disease
severity. We have also analyzed the diagnostic and prognostic
role of this biomarker, evaluating its ability to predict the lung
function decline during a 3-year follow-up period.Material and methodsPatient and study design
A cohort of 31 consecutive CF patients was prospectively
enrolled at the Pediatric Bronchopneumology and Cystic
Fibrosis Unit, Department of Pediatrics, University Hospital of
Catania, Italy. All subjects with CF were diagnosed using
accepted diagnostic criteria, including a minimum of two clinical
features consistent with the diagnosis and either two sweat Cl−
values >60 mEq or two disease-causing CF trans-membrane
conductance regulator (CFTR) mutations [17].
To increase the homogeneity of the CF population, patients
with clinical signs of exacerbation (decline of lung function
>10%, start of an antibiotic therapy, increase in coughing,
clinical signs of infection, or signs of infection in terms of C-
reactive protein elevation or differential counts) were excluded
from analysis.
Thirty non-smoking healthy controls (HS group) were
recruited without history of arterial hypertension, diabetes and
neoplastic, cardiovascular, inﬂammatory, renal, lung, or endo-
crine diseases. None of these subjects was under medical
treatment.
Every participant gave a fully informed approval to take part
in the study. The local Ethics Committee approved the study
protocol.
Collection of blood, procedures and deﬁnitions
Blood samples were drawn from all patients in fasting state in
the morning during their regular visits.
All spirometric tests used in the present studywere performed
in a Pulmonary Physiology Unit every 4 months. Forced vital ca-
pacity (FVC) and the FEV1were recorded. During the spirometric
test, three forced expiratory manoeuvres were performed, andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe best result was registered. All values were expressed in per-
centage of the predicted values for age, height, and gender [18].
Screening for suspected exocrine pancreas insufﬁciency was
assessed by faecal fat dosage, faecal chymotrypsin, and faecal
elastase [19].
Patients with CF were classiﬁed according to spirometry re-
sults. In particular, an FEV1 80% of predicted was considered
normal, whereas a mild respiratory dysfunction was deﬁned by a
FEV1 level of 60–80%. A moderate respiratory disorder was
indicated by a FEV1 value of 40–60% of predicted; a severe res-
piratory disorder was identiﬁed by a FEV1 <40% of predicted.
After spirometry, sputum induction was performed according
to a standard operating procedure [20]. Sputum was collected
into two containers. One specimen was submitted for compre-
hensive microbiology per CF consensus guidelines [21]. The
second specimenwas processed for themeasurement ofHMGB1,
which was measured by ELISA, using commercially available an-
tibodies (IBL Shino Test Corporation, Hamburg, Germany).
The number of prior-year APE and the incidence of hospi-
talization were also evaluated. In particular, CF patients hos-
pitalized for APE had at least four of the following criteria: 10%
or greater decrease in baseline FEV1, increased cough or
sputum production, change in sputum character, dyspnoea,
tachypnea, fever, weight loss, 5% or greater decrease in O2
saturation, new or worsening crackles on lung auscultation, or
ﬁndings on chest X-ray study consistent with pneumonia [22].
Prospective follow-up
After baseline assessments, patients were followed prospec-
tively until the end of the observation period of 3 years or until
the primary study end point was reached. This latter was
deﬁned by a worsening of pulmonary function established by
reduction of FEV1 more than 10%.
Statistical analyses
Statistical analyses were performed with NCSS for Windows
(version 4.0; NCSS LLC, Kaysville, UT, USA), the MedCalc
software (version 11.0; MedCalc Software Acacialaan, Ostend,
Belgium), and the GraphPad Prism package (version 5.0;
GraphPad Software, Inc., San Diego, CA, USA). Differences
between groups were established by unpaired t test or by
analysis of variance followed by Bonferroni test for normally
distributed values and by Kruskal-Wallis analysis followed by
Dunn’s test for nonparametric values. Dichotomized values
were compared using the χ2 test. Logistic regression analysis
was performed to detect potential relationships between
dichotomous variables and HMGB1. Pearson or Spearman
correlation coefﬁcients were used as appropriate to test cor-
relations between HMGB1 and other variables. Receiver
operating characteristics (ROC) analysis was employed toious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e1–368.e9
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HMGB1 to ﬁnd the best cut-off values capable of identifying the
lung function decline and APE in CF patients. Kaplan-Meier
curves were generated to assess incidence of the progression
of lung disease in subjects with serum and sputum HMGB1
values above and below the optimal ROC-derived cut-off levels.
Differences were evaluated using the log-rank test. Adjusted
risk estimates for CF worsening were calculated using univariate
followed by multivariate Cox proportional hazard regression
analysis. All results were considered signiﬁcant if p was <0.05.ResultsPatients’ baseline characteristics
Baseline clinical characteristics of our study subjects are sum-
marized in Table 1. The HS group was well matched for sex and
age with the study group (HS group: 15 female and 15 male; age
23.2 ± 11.3 years; study group: 14 females and 17 males; age
21.2 ± 13.9 years).
Twenty-three patients (74%) were characterized by a Δ508
CFTR gene mutation, whereas eight patients (26%) had a non-
F508del CFTR genotype. In particular, one patient had the geno-
type L1077P/D1152H, one patient had the mutation1717-1G>A/
Q220X, two patients had the mutation W1282X/P5L, and four
patients were characterized by the mutation N1303K/N1303K.
P. aeruginosa pulmonary isolation was assessed in 20 patients
(64.5%; a primo-colonization was revealed in seven patients),
whereas a positive culture for Staphylococcus aureus was
detected in six (19%) patients. In four patients, we revealed a
co-colonization.
The mean FEV1 and the mean FVC were 61.1 ± 32.5% and
76.2 ± 27.5% of predicted, respectively. Of the 31 patients,TABLE 1. Main baseline characteristics of the study cohort and stati
progression assessed during the follow-up period
Baseline
(n[ 31)
Gender (M/F) 17/14
Age, years 21.2 ± 13.9
BMI 20.2 ± 4.5
ΔF 508 / ΔF 508 / 23 (74%)
ΔF 508 / other 8 (26%)
FVC % predicted 76.2 ± 27.5%
FEV1 % predicted 61.1 ± 32.5%
Pseudomonas aeruginosa 20 (64.5%)
Staphylococcus aureus 6 (19%)
APE events/year 0.8 ± 1.3
Exocrine pancreatic failure 21 (68%)
Chronic azithromycin 11 (35%)
Inhaled steroids 27 (87%)
Colistin inhalation 14 (45%)
C reactive protein, mg/L, median (IQR) 0.5 (0.2–0.8)
Serum HMGB1, ng/mL 9.2 (5.4–75.4)
Sputum HMGB1, ng/mL 5.1 (2.5–25.6)
BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in the ﬁrst s
interquartile range (25–75%).
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Ineight (26%) presented FEV1 80%, nine (29%) had FEV1
60–80%, in seven (22.5%) cases FEV1 was between 40% and
60%, and seven (22.5%) patients had FEV1 <40%.
Serum HMGB1 levels were signiﬁcantly higher than those
measured in healthy controls (median (range): 9.2 (5.4–75.4) vs.
1.8 (1.4–2.5) ng/mL, p <0.0001), as well as sputumHMGB1 levels
(5.1 (2.5–25.6) vs. 1.1 (0.8–1.8) ng/mL, p <0.0001). We analyse
HMGB1 according to CF genotype, but we did not ﬁnd statistical
signiﬁcant differences of its levels among the different groups.
We have also demonstrated that patients with worse pulmo-
nary functions, revealed by spirometric data, such as low FEV1
percentage, had high HMGB1 levels (77.2 (51.2–112.3) ng/mL;
(28.9 (15.6–43.2) ng/mL), in both serum and sputum, respectively.
Moreover, according to APE events occurring during the
study period, patients were subdivided into two groups: APE
group (n = 12) and No-APE group (n = 19). In the ﬁrst group,
both serum and sputum HMGB1 values were signiﬁcantly
higher than those observed in patients without acute pulmo-
nary exacerbation (serum HMGB1: 73.5 (5.4–103.3) vs. 7.6
(3–22.4) ng/mL, p 0.005; sputum HMGB1: 15.8 (11–35.4) vs.
3.2 (2.2–10.2) ng/mL, p 0.01).
In addition, 21 (68%) patients with exocrine pancreas
insufﬁciency were characterized by higher levels of serum
HMGB1 than those observed in patients with normal pancreas
function (38.6 (3.9–81.3) vs. 8.8 (7.6–9.4) ng/mL, p 0.01),
whereas no differences in HMGB1 levels assessed in the sputum
have been detected. Fig. 2 summarizes these data.
Univariate correlations and multiple regression
analysis
Serum HMGB1 was strictly correlated with markers of pul-
monary dysfunction and inﬂammation. In particular, a direct
correlation was demonstrated between serum HMGB1 and C-stical differences between patients with or without lung disease
Progressor
(n[ 14)
Non-progressor
(n[ 17) p
9/5 8/9 0.35
21.5 ± 9.5 21 ± 17 0.93
20.5 ± 5.3 20.1 ± 6.4 0.66
14 (100%) 9 (53%) 0.04
0 8 (47%) 0.03
67.7 ± 28.3 85.2 ± 24.6 0.10
47.7 ± 25.4 80.5 ± 26 0.002
14 (100%) 6 (35%) 0.03
4 (28%) 2(11%) 0.28
1.5 ± 1.7 0.2 ± 0.4 0.008
14 (100%) 7 (41%) 0.01
5 (35%) 6 (35%) 0.45
13 (92%) 14 (82%) 0.31
8 (57%) 6 (35%) 0.22
0.7 (0.4–2.6) 0.2 (0.1–0.6) 0.008
76.5 (15.3–103.7) 6.9 (2.3–8.9) 0.0002
28.9 (12.9–34.5) 2.5 (2.1–4.1) <0.0001
econd; APE, acute pulmonary exacerbation; HMGB1, high-mobility group box 1; IQR,
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e1–368.e9
FIG. 2. HMGB1 levels in CF patients and control subjects, according to lung function, pancreas failure and pulmonary exacerbations. *FEV1 <40% vs.
FEV1 >80%; p 0.03. APE, acute pulmonary exacerbation; CF, cystic ﬁbrosis; FEV1, forced expiratory volume in the ﬁrst second; HMGB1, high-mobility
group box 1; HS, healthy subjects; NS, p >0.05.
368.e5 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIreactive protein (CRP) (r 0.65; p 0.0001), APE events (r 0.54; p
0.001), and number of hospitalizations (r 0.35; p 0.001),
whereas an inverse correlation was found with baseline FEV1
(r −0.48; p 0.01) and FVC (r −0.52; p 0.004). Serum HMGB1
was closely related to HMGB1 levels assessed in the sputum
sample (r 0.88; p <0.0001). The same relationships found with
serum HMGB1 were conﬁrmed with sputum HMGB1 (Fig. 3).
Using serum and sputum HMGB1 as dependent variables in a
multiple regression model, including all previously reported
univariate correlates (CRP, APE events, number of hospitali-
zations, baseline FEV1, and FVC), only the associations with
CRP (β = 0.61, p 0.004), FVC (β −0.76, p 0.008), and FEV1
(β −0.70, p 0.001) remained signiﬁcant.
Moreover, to assess the relationship between P. aeruginosa
infection and serum and sputum HMGB1 as independent var-
iables, we performed a logistic regression analysis. We revealed
that only sputum HMGB1 remained included in the model
(standardized coefﬁcient β 0.264; p 0.01).
HMGB1 as a diagnostic marker of APE and lung disease
progression
ROC analyses were performed in order to deﬁne the diagnostic
proﬁle of serum and sputum HMGB1 in identifying APE eventsClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectand decline of lung function among CF patients. Analysing these
biomarkers for APE events, we have assessed that the AUC for
serum HMGB1 was 0.792. When the cut-off values were set at
9.5 ng/mL, sensitivity and speciﬁcity of the marker used for the
diagnosis were 75% and 73.7%, respectively. A similar proﬁle
was obtained evaluating sputum HMGB1. The AUC was 0.770
associated with 91.7% and 73.7% of sensitivity and speciﬁcity,
respectively, when the cut-off value was set at 4.8 ng/mL. We
did not ﬁnd statistical differences between HMGB1 levels, both
in serum and in sputum, and CRP in identifying APE events (p
0.06).
We have also assessed the role of HMGB1 in detecting the
worsening of lung function. In particular, the AUC for serum
HMGB1 was 0.973, with a sensitivity and speciﬁcity of 92.9%
and 94.1%, respectively, when the cut-off value was set at
9.5 ng/mL. The AUC of sputum HMGB1 was 0.958. When the
cut-off value was set at 5.3, the sensitivity and speciﬁcity were
92.9% and 94.1%, respectively. We did not ﬁnd statistical dif-
ferences between these two biomarkers, whereas their proﬁles
were better than those obtained with CRP (AUC 0.773;
sensitivity 92.9% speciﬁcity 58.8%; best cut-off value 0.3 mg/L; p
0.006). Figure 4 schematizes these data.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e1–368.e9
FIG. 3. Univariate baseline statistical correlations of sputum and serum high-mobility group box 1 (HMGB1).
CMI Chirico et al. HMGB1 and lung function decline in cystic ﬁbrosis 368.e6HMGB1 and lung disease progression
During the observational period, 14 patients (45%) reached the
end point, represented by pulmonary disease progression,
established by the decreased FEV1 >10%. The remaining 17FIG. 4. Receiver operating characteristics curves of serum high-mobility grou
acute pulmonary exacerbation and lung function decline as status variables.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inpatients (55%), who did not experience a progression in CF,
completed the whole observational period. Table 1 displays
main data and statistical differences between patients with or
without lung disease progression during the follow-up period.p box 1 (HMGB1), sputum HMGB1, and C-reactive protein, considering
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e1–368.e9
FIG. 5. Kaplan-Meier survival curves of end point (lung function decline
during the follow-up period) in patients with serum and sputum high-
mobility group box 1 (HMGB1) levels above and below the optimal
receiver operating characteristics cut-off level.
368.e7 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIIn particular, progressor subjects presented signiﬁcantly
increased serum and sputum HMGB1 values at baseline
compared with non-progressors (serum HMGB1: 76.5
(15.3–103.7) vs. 6.9 (2.3–8.9), p 0.0002; sputum HMGB1: 28.9
(12.9–34.5) vs. 2.5 (2.1–4.1), p <0.0001).
Kaplan-Meier survival curves in patients with serum and
sputum HMGB1 levels above and below the optimal cut-off are
presented in Fig. 5.
Patients with serum HMGB1 values above 9.5 ng/mL expe-
rienced a signiﬁcantly faster evolution to decline of lung func-
tion (log-rank (χ2) 7.2; p 0.007; hazard ratio 0.28; 95% CI
0.1–0.8) with a mean follow-up time to progression of 20
months, compared with 32 months for serum HMGB1 below
the cut-off. A parallel trend was observed analysing sputumTABLE 2. Univariate and multivariate Cox proportional hazards re
Univariate analysis
HR 95% CI p
ΔF508 genotype 1.03 1.01–1.06 0
FEV1 0.98 0.96–0.99 0
APE events, n 1.08 1.03–1.16 0
PA infection 1.12 1.05–1.27 0
EPI 1.15 0.73–1.18 0
CRP 1.02 1.01–1.04 0
Serum HMGB1 1.04 1.01–1.08 0
Sputum HMGB1 1.07 1.08–1.22 0
APE, acute pulmonary exacerbation; CRP, C-reactive protein; EPI, exocrine pancreas insufﬁci
box 1; HR, hazard ratio; PA, Pseudomonas aeruginosa.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectHMGB1 levels (log-rank (χ2) 11; p 0.0009; hazard ratio 0.15;
95% CI 0.05–0.4).
Univariate/multiple Cox regression analysis and
incidence of decline of lung function
To identify putative risk factors associated with incidence of
decline of lung function, we performed a Cox regression
analysis, inserting in the model all variables that were different
at baseline in patients who reached the end point during the
whole follow-up period (ΔF 508 genotype, FEV1, P. aeruginosa
infection, APE events per year, exocrine pancreatic failure,
CRP, serum and sputum HMGB1).
Univariate analysis showed that ΔF508 genotype, FEV1,
P. aeruginosa infection, exocrine pancreatic failure, CRP, and
serum and sputum HMGB1 values were signiﬁcantly associated
with end point. A multiple Cox regression was constructed,
simultaneously inserting into the model all of the variables
found to be signiﬁcantly associated with end point at univariate
analysis. Results from this analysis indicated that serum and
sputum HMGB1 as well as genotype, P. aeruginosa infection, and
CRP predicted higher risk of decline of lung function. In detail,
an increase of serum HMGB1 was associated with a 5%
increased risk of pulmonary disease progression (hazard ratio
1.05; 95% CI 1.02–1.09; p 0.002), whereas elevated sputum
HMGB1 was related to a 10% increased risk (hazard ratio 1.10;
95% CI 1.03–1.18; p 0.0004). Table 2 summarizes data from
univariate and multivariate Cox analysis.DiscussionHMGB1 mediates inﬂammatory lung disease in CF and it is
closely related with airway infection and chronic neutrophilic
recruitment.
We demonstrated that CF patients are characterized by
higher levels of this alarmin, both in sputum and in serum, than
healthy subjects, supporting the hypothesis that HMGB1 plays a
critical role in CF pathogenesis. Moreover, whereas serumgression model for incidence of lung disease progression
Multivariate analysis
HR 95 % CI p
.02 1.02 1.01–1.04 0.03
.03 0.97 0.96–1.02 0.10
.01 1.04 1.01–1.07 0.02
.002 1.08 1.04–1.18 0.001
.23
.04 1.01 0.98–1.03 0.08
.001 1.05 1.02–1.09 0.002
.003 1.10 1.03–1.18 0.0004
ency; FEV1, forced expiratory volume in the ﬁrst second; HMGB1, high-mobility group
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 368.e1–368.e9
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sputum HMGB1 is more speciﬁc for pulmonary damage, as
demonstrated by its exclusive correlation with airway
P. aeruginosa infection, FEV1, and APE events.
It is well known that HMGB1 in CF airways plays a critical
role for neutrophil recruitment and persistent infection in the
lung, due to its proinﬂammatory properties and through a
direct inhibition of macrophage ability to phagocytose bacteria,
thus representing an ideal therapeutic target [23,24].
It was demonstrated that pulmonary neutrophil recruitment,
tissue injury, and inﬂammation, induced by a direct HMGB1
instillation into the lung, have been inhibited by co-administration
of anti-HMGB1antibodies [25]. These effects have been conﬁrmed
by Entezari et al., who revealed, in animals, that neutralizing anti-
HMGB1 antibodies could rescue the macrophage dysfunction
with a reduction of P. aeruginosa-induced neutrophilic inﬂamma-
tion, bacterial counts in the lung and alveolar injury, highlighting the
role of HMGB1 on bacterial clearance beyond its inﬂammatory
properties [26]. Moreover, HMGB1 could regulate inﬂammation
and infection through the autophagy process. Recently, in CF pa-
tients, a functional impairment of autophagy, which plays a central
regulator role of inﬂammatory responses modulating inﬂamma-
some activation and nuclear factor-κB activity, was demonstrated,
with susceptibility to severe infections [27].
Our results revealed that HMGB1 represents a useful
biomarker, able to detect exacerbations of pulmonary disease
and lung function decline with high sensitivity and speciﬁcity.
Patients with APE were, in fact, characterized by high HMGB1
levels, as well as CF patients with low FEV1 values. Moreover,
sputum HMGB1 gave a better diagnostic proﬁle than that ob-
tained by CRP, characterized by a low speciﬁcity.
There is a paucity of data in the literature examining the
relationships between longitudinal changes in airway inﬂam-
mation and lung function in CF. In a retrospective review of
sputum biomarkers, measured in multiple CF clinical trials,
longitudinal analyses revealed signiﬁcant associations between
increases in neutrophil elastase and decreases in FEV1 [7]. BAL
rather than sputum was also used to investigate biomarkers of
airway inﬂammation, such as neutrophil counts, free neutrophil
elastase, and interleukin-8, but none of these cytokines pre-
dicted a decline in lung function [28].
Being able to use biomarkers to monitor disease progression
and predict those subjects at risk of a rapid decline in lung
function would have a signiﬁcant impact on clinical practice in CF.
Our ﬁndings suggest that sputum and serum HMGB1 are
suitable predictive biomarkers of lung function decline over a 3-
year follow-up period. Moreover, sputum and serum HMGB1
represent novel riskmarkers of respiratory disease progression in
CF patients. If predictive value of baseline P. aeruginosa infection,
altered FEV1, and high CRP levels conﬁrms the general suggestionClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inthat an already impaired lung function and chronic inﬂammation
are important factors for the subsequent progression of pulmo-
nary disease, remarkably, sputum and serum HMGB1 showed a
most impressive predictive power in such a contest even after
adjustment for confounding factors. HMGB1 would not be a
simple surrogate index of inﬂammation, but a marker on its own,
predicting lung disease progression, beyond the information
provided by other inﬂammatory markers, such as CRP.
The present study has some limitations that should be
mentioned. It was a single-centre and hypothesis-generating
study, involving a relatively small cohort of patients. Conﬁr-
mation in wider cohorts is indispensable to attribute general
validity to our reports. However, the primary end point was
reached by 45% of the participants, and the statistical model
was powerful enough to establish independent relationships
between HMGB1 and progression of lung disease.
In conclusion, HMGB1 represents an important inﬂamma-
tory modulator in airway secretions of subjects with CF. The
determination of sputum and serum HMGB1 has predictive
value for APE and lung function decline among CF patients,
allowing monitoring of the disease activity and the response to
therapy. HMGB1 itself could be a feasible treatment target in
CF. Inhibitors of HMGB1 are currently being developed for
application in sepsis and other inﬂammatory diseases.
In CF, an intervention that blocks the dysregulated activation
of the innate immune system could potentially ameliorate
excessive chronic neutrophilic inﬂammation that contributes to
disease progression.
Further studies are needed to clarify the predictive and
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